Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed + Diphtheria and Tetanus toxoids adsorbed
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tetanus
Conditions
Tetanus, Diphtheria, Pertussis
Trial Timeline
Mar 1, 2014 → Mar 1, 2015
NCT ID
NCT02089347About Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed + Diphtheria and Tetanus toxoids adsorbed
Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed + Diphtheria and Tetanus toxoids adsorbed is a phase 3 stage product being developed by Sanofi for Tetanus. The current trial status is completed. This product is registered under clinical trial identifier NCT02089347. Target conditions include Tetanus, Diphtheria, Pertussis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02089347 | Phase 3 | Completed |
Competing Products
10 competing products in Tetanus